Remsima™ – the first biosimilar infliximab
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s. a Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN v Praze
Published in:
Gastroent Hepatol 2014; 68(2): 178-179
Category:
Drug Profile
Sources
1. Urbánek K. První biosimilární monoklonální protilátka – infliximab. Klin Farmakol Farm 2014; 28(1): 19–22.
2. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann Rheum Dis 2013; 72(10): 1605–1612. doi: 10.1136/annrheumdis-2012-203091.
3. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72(10): 1613–1620. doi: 10.1136/annrheumdis-2012-203090.
4. SÚKL. Souhrn údajů o přípravku Remsima. Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0194345&tab=texts.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2014 Issue 2
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- Metamizole in the Treatment of Acute Postoperative Pain
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Most read in this issue
- Budd-Chiari syndrome and TIPS – 21 years’ experience
- Hereditary angioedema as a cause of abdominal pain
- Therapy of portal hypertension using transjugular intrahepatic portosystemic shunt – first 1,000 procedures in UH Hradec Kralove
- Modern diagnostics of Lynch syndrome